How are pharmaceutical companies closer to innovative drugs?

With the changes in the social environment and people's lifestyles, frequently-occurring diseases, common diseases and major diseases have seriously jeopardized people's health. Research and development of new targets or multi-target innovative drugs is an urgent need for clinical treatment, as well as a hot spot and a commanding height for economic growth. At the same time, China's pharmaceutical innovation environment is gradually improving, the policy continues to improve, the drug review and approval system is in-depth reform, the investment environment is continuously optimized, and the independent research and development capabilities are improved. The domestic innovative drug research and development is ushering in the "golden age." However, in the face of tremendous opportunities, in front of China's innovative drugs is a series of practical problems that hinder pharmaceutical innovation. In addition to research and development funds, lack of innovative talents, etc., the failure of extensive cooperation between medical research companies is also a key issue. From a global perspective, due to the pressure of research and development costs, the closed and independent drug development model that the pharmaceutical industry has been pursuing has not adapted much. It is imperative to cooperate in the development of new drugs.

“Pre-clinical research on drugs” is the most complicated part of the drug development process, and it is a key stage for the development of the drug. Since the results of animal experiments cannot fully predict the clinical results, after the clinical trial is actually started, there is about 40% failure rate in Phase II clinical trials and 50% failure rate in Phase III clinical trials. For pharmaceutical companies, it is necessary to pay attention to the early drug-based evaluation of innovative drugs to reduce the clinical failure rate, thereby reducing the economic losses caused by late clinical trial failure. Select a professional drug screening and pharmacodynamic evaluation service platform to evaluate and screen innovative drugs, implement early elimination, move the barriers as far as possible, improve the quality of new drug research in the later period, and effectively reduce the investment and risk of innovative drug research and development.

The demand for drug efficacy evaluation service platforms for drug candidates has become increasingly fierce, and pharmacodynamic evaluation agencies have emerged. Gaosheng Medicine is a company that adheres to the concept of “innovation-driven, technologically strong country” and insists on the research of innovative drugs. The pharmaceutical screening and pharmacodynamic evaluation platform built by the company is a model animal construction experience with more than 10 years. It provides medical model animal and drug screening services for thousands of scientific research units and pharmaceutical companies. It has rich project experience and has been successfully constructed. Hundreds of disease models, such as myocardial ischemia model, MCAO model, rat retina ischemia-reperfusion injury model, myocardial ischemia-reperfusion model, neonatal rat hypoxia-ischemia model, and so on. The platform has established strategic partnerships with the Institute of Biochemistry and Cell Biology of the Chinese Academy of Sciences and Griffith University of Australia. It also cooperates with the Chongqing Pharmacodynamics Evaluation Center, Chongqing Institute of Chinese Medicine, Third Military Medical University School of Pharmacy, Chongqing Medical College. The university has established a good cooperative relationship. As the first drug screening and pharmacodynamic evaluation platform in Southwest China, it is actively building a drug screening and pharmacodynamic evaluation research engineering center with the support of governments at all levels.

The center has SPF-level animal laboratory, 10,000-level cell room and functional laboratory, high-throughput high-content screening platform and ion channel target drug screening platform, which has been equipped with complete functions, reliable performance, high degree of automation, and part It has the world's advanced level of sample processing and testing equipment. It can complete the main pharmacodynamics and general pharmacology research of anti-inflammatory immunity, anti-tumor, cardiovascular system, respiratory system, mental diseases (insomnia, anxiety, depression, etc.) and metabolic diseases, satisfying the whole animal experiment, leaving Different levels of research needs, such as somatic cell experiments, mechanism studies, proteomics, and molecular biology studies, to determine whether new drugs are effective (effectiveness, superiority), the strength and extent of pharmacological effects (quantity-effect relationship, time- Relationship, structure-effect relationship). It provides professional drug screening and pharmacodynamic evaluation services for pharmaceutical companies, biomedical research institutes, new drug development centers, and new drug research and development institutions in universities and colleges.

New drug research and development is entering a new era, innovative drugs are also emerging, pharmaceutical companies still need to have confidence in the future, use their own advantages, break the traditional closed development model, seek cooperation and win-win, keep up with the pace of world drug development, away from Innovative drugs are closer!